Genome-wide association studies have identified numerous genetic loci for spirometic measures of pulmonary function, forced expiratory volume in one second (FEV1), and its ratio to forced vital capacity (FEV1/FVC). Given that cigarette smoking adversely affects pulmonary function, we conducted genome-wide joint meta-analyses (JMA) of single nucleotide polymorphism (SNP) and SNP-by-smoking (ever-smoking or pack-years) associations on FEV1 and FEV1/FVC across 19 studies (total N = 50,047). We identified three novel loci not previously associated with pulmonary function. SNPs in or near DNER (smallest PJMA = 5. 00×10−11), HLA-DQB1 and HLA-DQA2 (smallest PJMA = 4. 35×10−9), and KCNJ2 and SOX9 (smallest PJMA = 1. 28×10−8) were associated with FEV1/FVC or FEV1 in meta-analysis models including SNP main effects, smoking main effects, and SNP-by-smoking (ever-smoking or pack-years) interaction. The HLA region has been widely implicated for autoimmune and lung phenotypes, unlike the other novel loci, which have not been widely implicated. We evaluated DNER, KCNJ2, and SOX9 and found them to be expressed in human lung tissue. DNER and SOX9 further showed evidence of differential expression in human airway epithelium in smokers compared to non-smokers. Our findings demonstrated that joint testing of SNP and SNP-by-environment interaction identified novel loci associated with complex traits that are missed when considering only the genetic main effects.
Spirometric measures of pulmonary function, particularly forced expiratory volume in one second (FEV1) and its ratio to forced vital capacity (FEV1/FVC), are important clinical tools for diagnosing pulmonary disease, classifying its severity, and evaluating its progression over time. These measures also predict other morbidities and mortality in the general population [1]–[3]. Genetic factors likely play a prominent role in determining the maximal level of pulmonary function in early adulthood and its subsequent decline with age [4], [5]. A relatively uncommon deficiency of α-1 antitrypsin, due to homozygous mutations of the SERPINA1 gene, is a well-established genetic risk factor for accelerated decline in pulmonary function, but it accounts for little of the population variability in pulmonary function. Genome-wide association studies (GWAS) have identified many common genetic variants underlying pulmonary function. The first GWAS of pulmonary function implicated HHIP for FEV1/FVC [6], [7]. GWAS meta-analyses for FEV1/FVC and FEV1 from the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) and SpiroMeta Consortia have together identified 26 additional novel loci in or near the following genes: ADAM19, AGER-PPT2, ARMC2, C10orf11, CCDC38, CDC123, CFDP1, FAM13A, GPR126, HDAC4, HTR4, INTS12-GSTCD-NPNT, KCNE2, LRP1, MECOM (EVI1), MFAP2, MMP15, NCR3, PID1, PTCH1, RARB, SPATA9, TGFB2, THSD4, TNS1, and ZKSCAN3 [8]–[10]. Inhaled pollutants, especially cigarette smoking, can have important adverse effects on pulmonary function. Candidate gene studies have not consistently identified interactions with cigarette smoking in relation to pulmonary function. Despite the importance of smoking and other environmental factors in the etiology of many complex human diseases and traits, few GWAS have incorporated gene-by-environment interactions [11]–[14]. Meta-analyses are generally necessary to provide sufficient sample size to detect moderate effects, and methods for joint testing of single nucleotide polymorphism (SNP) main effects and SNP-by-environment interactions in the meta-analysis setting have only recently been developed [15], [16]. This strategy has the potential to identify novel loci that would not emerge from analyses based on the SNP main or interactive effects alone [15]–[17]. The well-documented and consistent deleterious effect of cigarette smoking on pulmonary function [18] makes it a good candidate for such an approach, since genetic factors may have heterogeneous effects on pulmonary function depending on smoking exposure. We conducted genome-wide joint meta-analyses (JMA) of SNP and SNP-by-smoking interaction (ever-smoking or pack-years) associations with cross-sectional pulmonary function measures (FEV1/FVC and FEV1) in 50,047 study participants of European ancestry.
Three genes (DNER, KCNJ2, and SOX9) harboring or flanking novel genome-wide significant SNPs were selected for follow-up mRNA expression profiling in human lung tissue and a series of primary cells. Transcripts of all three genes were found in lung tissue, airway smooth muscle, and bronchial epithelial cells; DNER and KCNJ2 transcripts were also found in peripheral blood cells (Table S10). In a separate line of investigation, using the publically available Gene Expression Omnibus repository [27], [28], we found that the expression profiling of DNER and SOX9 showed differential expression in human airway epithelium of smokers compared to non-smokers (Figure S2A and S2B) [29]. Expression profiling of KCNJ2 did not show statistically significant differential expression by smoking status (Figure S2C) [29]. We also identified novel genome-wide significant SNPs in the HLA-DQ region, but we did not examine HLA-DQ expression given the known expression of class II MHC antigens on a range of airway cell types [30], [31]. However, the lead SNP in this region (rs7764819) was associated with statistically significant effects on HLA-DQB1 expression (P = 1. 2×10−14), according to an eQTL analysis database of lymphoblastoid cell lines [32].
Few GWAS have accounted for potential interaction with environmental risk factors. To identify novel genetic risk factors that are missed when considering only genetic main effects [33], we used the newly available JMA method [15] to simultaneously summarize regression coefficients for the main SNP and SNP-by-smoking interactive effects in 50,047 participants from 19 studies, based on models that were fully saturated for the main effect of smoking. This study represents the most comprehensive analysis to date of gene-by-smoking interaction in relation to pulmonary function. We identified two novel loci (DNER and HLA-DQB1/HLA-DQA2) having highly significant evidence for association with FEV1/FVC. A third novel locus (KCNJ2/SOX9) was associated with FEV1. For the most significant SNPs at each of these three loci, there was no evidence for heterogeneity across the studies (smallest heterogeneity P = 0. 59), indicating that the associations were not driven by one or a few studies and thus reflect accumulation of evidence across the studies. None of these three loci had previously been associated with pulmonary function. The comparison of results with our prior GWAS meta-analysis of SNP main effects [10], using a comparable sample size, suggested that the SNP associations for our top SNPs were weaker in our previous analyses that examined only genetic main effects. However, our analyses and those of Manning et al. [14] suggest that some of the benefit of using the joint test for some findings comes from the careful adjustment for the environmental main effect. Thus, future studies aimed at replicating these findings may wish to jointly test the SNP main and interactive effects [15], [16], [33] instead of implementing a standard test of only the SNP main effects. If there is no evidence for interaction at a given locus, the saturation of the main effect of the environmental factor may be important. The joint testing is applicable for both candidate gene [15] and genome-wide [14] approaches. Further, there was minimal overlap in the top SNPs associated with FEV1/FVC and FEV1, as similarly observed in our previous GWAS meta-analyses of SNP main effects [8]–[10]. Given that the biological underpinnings of these discrepant association findings remain unknown, future studies should evaluate these genetic loci in the context of the pulmonary function measure for which they were originally implicated. Given that pulmonary function is a phenotype for which numerous genetic loci have been identified in GWAS and smoking is clearly associated with pulmonary function, it might seem surprising that none of the genome-wide significant SNPs implicated by the JMA demonstrated a substantial interaction per se. The lack of strong interactive effects does not negate the well-established harmful effects of cigarette smoking nor the need for broad public health campaigns to curb smoking. Instead, our findings demonstrate the value of applying the newly developed joint methods to uncover novel genetic risk factors that might shed light on the mechanisms leading to reduced pulmonary function. Our pattern of SNP main and interactive results resemble the patterns seen in another recent application of the same JMA method to incorporate the interaction with body mass index (BMI) into GWAS of type 2 diabetes traits (fasting insulin and blood glucose) [14]. In that study with a sample size of 96,453, nearly double that of ours, the top JMA finding had a corresponding interaction P value of 1. 6×10−4 [14]. In our study, the smallest interaction P value for our top JMA finding was 6. 9×10−3. In both our GWAS of smoking and pulmonary function and the recent GWAS of BMI and diabetes traits [14], the SNPs newly implicated by the JMA had marginally significant associations with the trait under study in models with no interaction term, but they became genome-wide significant when accounting for the environmental factor (cigarette smoking or BMI) and the SNP-by-environment interaction. Our JMA included careful modeling of the environmental factor to saturate the environmental main effects along with the interaction testing. In the GWAS of diabetes traits [14], the careful modeling of the environmental factor appeared to account for some of the novel findings from the JMA, consistent with the modest evidence for interaction [14]. Although our previous GWAS meta-analysis was conducted in ever/never-smoking strata, the regression models were not adjusted for smoking status or pack-years [10]. Some of our novel JMA findings compared with our previous GWAS findings may reflect, in part, the saturated modeling of the smoking main effect rather than the interaction per se. The current analysis of 50,047 participants included only 1,846 more participants than our previous GWAS meta-analysis of SNP main effects [10]. To evaluate the likelihood that this 3. 8% increase in sample size above that in our previous meta-analysis of pulmonary function was sufficient to explain our identification of these three novel loci at genome-wide statistical significance in the current JMA, we calculated the statistical power to detect genetic main associations (QUANTO [34]) with minor allele frequency (MAF) and β estimates comparable to the three genome-wide significant SNPs presented in Table 1. The current study (total N = 50,047 participants) had only 0. 7% to 4. 2% more statistical power than our previous GWAS meta-analysis (total N = 48,201 participants) [10], suggesting that the JMA-implicated SNPs are not merely reflective of increased power to detect genetic main effects. Instead, our novel JMA findings demonstrate an advantage of the method used to jointly test the SNP and SNP-by-smoking interactive effects, including the benefit of the saturated modeling of the smoking main effect. SNPs located in the DNER gene were significantly associated with FEV1/FVC, even at the more conservative P value threshold of 1. 25×10−8. The JMA results for DNER SNPs were driven by both smoking-adjusted main effects and interaction with quantitative smoking history. The DNER protein product is a ligand of the Notch signaling pathway that has been implicated in neuronal differentiation and maturation [35], [36], adipogenesis [37], and hair-cell development [38]. The Notch pathway is a critical controller of cellular differentiation in multiple organs including the lung [39], [40]. Interestingly, the expression levels of many members of the Notch signaling cascade are significantly altered in airway epithelial cells of smokers [41]. We confirmed the expression of DNER transcripts in lung and peripheral cells, and by mining publicly available transcriptional profiling databases [29], we found that DNER is expressed in bronchial epithelial cells of non-smoking adults and, importantly, its expression is significantly higher in smokers (Figure S2A). Collectively, these results suggest that DNER plays a role in cigarette smoke-induced airflow obstruction and further corroborate the importance of the Notch signaling circuitry in the pathogenesis of obstructive lung disease. Also in relation to FEV1/FVC, intergenic SNPs between HLA-DQB1 and HLA-DQA2 exceeded the more conservative genome-wide significance threshold. The eQTL analyses indicated that the lead SNP is associated with expression of HLA-DQB1 specifically. However, the major histocompatibility complex region is highly polymorphic with complex LD patterns, and a few specific functional SNPs might explain the observed associations [42]. Genetic variations within this region have been associated with several autoimmune disorders [43] and asthma [24], [44], [45], and an interaction between HLA variants and cigarette smoking has been previously implicated [46]. We found little evidence for interaction with smoking at this locus, suggesting that the JMA results were primarily driven by smoking-adjusted genetic main effects. It is most likely that this locus was not identified in our previous GWAS meta-analysis, because the genetic main associations were not evaluated with careful adjustment for smoking status and pack-years. Adjustment for smoking in the current analysis may have removed residual variance in the outcome that is not attributable to genetic variation [14], thus making the identification of the newly associated SNPs possible. Intergenic SNPs between KCNJ2 and SOX9 were significantly associated with FEV1 at the standard P value threshold, but not the more conservative threshold. Similar to the HLA region, it appears that the JMA results for the KCNJ2/SOX9 region were primarily driven by smoking-adjusted genetic main effects. This region is enriched for long-range regulatory elements for SOX9, although the possibility of this region containing KCNJ2 regulatory elements cannot be discounted [47]. KCNJ2 is a member of the inwardly-rectifying potassium channel family, which regulates membrane potential and cell excitability and is expressed in many tissues including myocardium, neurons, and vasculature. This potassium channel also affects human bronchial smooth muscle tone and airflow limitation [48]. Dominant negative mutations in KCNJ2 cause the Andersen syndrome, characterized by ventricular arrhythmias, periodic paralysis, and a number of skeletal and cardiac abnormalities [49]. SOX9 is a transcription factor that is essential for cartilage formation, [50] but it is also abundantly expressed in other tissues including the respiratory epithelium during development [51]. Sox9−/− and Sox9+/− mice have multiple skeletal anomalies and severe tracheal cartilage malformations and die prematurely from respiratory insufficiency [50], [52]. Mutations in SOX9 cause campomelic dysplasia characterized by skeletal defects and autosomal sex reversal [53]. These individuals develop respiratory distress due to chest wall abnormalities, narrowed airways resulting from tracheobronchial defects and hypoplastic lungs [54]. We confirmed that KCNJ2 and SOX9 transcripts were present in human lung tissue and peripheral cells. Using publicly available microarray data [29], we established that SOX9 is expressed in human airway epithelial cells and its expression is significantly down-regulated in smokers relative to non-smoking adults (Figure S2B). Taken together, these results suggest that SOX9 may be involved in cigarette smoke-induced airflow obstruction, but further investigation is required to elucidate putative mechanisms. Most of the previously implicated SNPs had genome-wide significant (or nearly significant) associations with pulmonary function in the JMA, but some were associated with pulmonary function at P values that did not approach the genome-wide statistical significance threshold in the JMA analysis. This pattern has two possible explanations. First, the identification of these SNPs at genome-wide statistical significance in our most recent analysis [10] required a sample size of nearly 95,000 individuals, which was obtained by combining discovery and replication cohorts, including additional genotyping on thousands of participants from studies without GWAS data. In the current analysis, the sample size is greatly reduced because of the need for detailed quantitative smoking data and because we were unable to perform additional genotyping in studies without GWAS data. Second, Manning et al. [15] showed that a meta-analysis of main SNP effects has slightly greater power than the JMA under the scenario of no interaction, so it is not surprising that a few of the prior SNP findings had varying levels of significance between our prior GWAS meta-analyses [8]–[10] and the current JMA study. While our sample size of over 50,000 study participants is large, and the study of Manning et al. [14] examining SNP-by-BMI interaction in relation to fasting insulin is nearly twice as large, identification of interactions is challenging from a statistical power perspective. Given the multiple testing issues in genome interaction testing, even larger sample sizes will likely be needed to identify gene-by-environment interactions with rare variants or with the modest effect sizes that we generally expect. Nonetheless, our findings exemplify the greater power achieved by using the joint methods, such as those reported by Manning et al. [15] and Kraft et al. [16], [33], to incorporate interaction with a clearly associated environmental risk factor. The novel genetic loci identified here for pulmonary function would have remained unknown using standard GWAS approaches.
Nineteen independent studies contributed to our analyses. All study protocols were approved by the respective local Institutional Review Boards, and written informed consent for genetic studies was obtained from all participants included in our analyses. Of the 19 studies contributing to our analyses, 18 studies came from the CHARGE [8], [55] or SpiroMeta [9] Consortium: Age, Gene, Environment, Susceptibility (AGES) – Reykjavik Study [56]; Atherosclerosis Risk in Communities (ARIC) Study [57]; British 1958 Birth Cohort (B58C) [58]; Coronary Artery Risk Development in Young Adults (CARDIA) [59], [60]; Cardiovascular Health Study (CHS) [61]; European Community Respiratory Health Survey (ECRHS) [62]; European Prospective Investigation into Cancer and Nutrition (EPIC, obese cases and population-based subsets) [63]; Framingham Heart Study (FHS) [64], [65]; Health, Aging, and Body Composition (Health ABC) Study [66]; Northern Finland Birth Cohort of 1966 (NFBC1966) [67], [68]; Multi-Ethnic Study of Atherosclerosis (MESA) [69], [70]; Rotterdam Study (RS-I, RS-II, and RS-III) [71]; Swiss Study on Air Pollution and Lung Diseases in Adults (SAPALDIA) [72]; Study of Health in Pomerania (SHIP) [73]; and TwinsUK [74]. We reached out to other population-based studies with GWAS genotyping and data available on cigarette smoking and pulmonary function, resulting in the inclusion of LifeLines [75]. Given the greater power needed to detect novel genetic loci with subtle gene-environment interaction regardless of the statistical method used [16], we chose to maximize statistical power to discover novel genetic loci by combining all available participants and to use the regression coefficients across the many different component studies as evidence for consistency. This approach was similarly taken by another large-scale GWAS consortium for discovering SNP main effects [24]. All studies were included in our previous GWAS meta-analysis of pulmonary function or the follow-up replication analyses, wherein their pulmonary function testing protocols were described [10]. For studies with spirometry at a single visit (B58C, LifeLines, MESA, NFBC1966, SHIP, RS-I, RS-II, and RS-III), we analyzed FEV1/FVC and FEV1 measured at that visit. For studies with spirometry at more than one visit, we analyzed measurements from the baseline visit (AGES, ARIC, CARDIA, CHS, ECRHS, EPIC obese cases, EPIC population-based, Health ABC, and SAPALDIA) or the most recent examination with spirometry data (FHS and TwinsUK). Smoking history (current-, past-, and never-smoking) was ascertained by questionnaire at the time of pulmonary function testing. Pack-years of smoking were calculated for current and past smokers by multiplying smoking amount (packs/day) and duration (years smoked). Table S11 presents the specific questions used to ascertain smoking history and pack-years in each of the 19 studies. Study participants were genotyped on various genotyping platforms, and standard quality control filters for call rate, Hardy-Weinberg equilibrium p-value, MAF, and other measures were applied to the genotyped SNPs (Table S12). To generate a common set of SNPs for meta-analysis, imputation was conducted with reference haplotype panels from HapMap phase II subjects of European ancestry (CEU) (Table S12) [76]. Imputed genotype dosage values (estimated reference allele count with a fractional value ranging from 0 to 2. 0) were generated for approximately 2. 5 million autosomal SNPs. Among participants with genome-wide SNP genotyping data, exclusions were made due to standard quality control metrics (call rate, discordance with prior genotyping, and genotypic and phenotypic sex mismatch among others), missing pulmonary function data, or missing covariate data (Table S13). Our analyses included 50,047 participants from 19 studies who passed their study-specific quality control and had complete data on pulmonary function and smoking. Each study transformed the pulmonary function measures to residuals using linear regression of FEV1/FVC (%) and FEV1 (mL) on age, age2, sex, and standing height as predictors. Principal component eigenvectors and recruitment site were also included as covariates to adjust for population stratification (if applicable). The residuals were converted to z scores (henceforth referred to as standardized residuals). We confirmed that smoking was inversely associated with the FEV1/FVC and FEV1 standardized residuals in all 19 studies (meta-analysis β = −0. 0030 and corresponding P<1×10−6 for pack-years of smoking). The FEV1/FVC and FEV1 standardized residuals were used as the phenotypes for genome-wide association testing with linear regression models, which included the following predictor variables: imputed SNP genotype dosages, smoking history (dichotomous variable, 0 = never-smokers and 1 = ever-smokers), smoking status (dichotomous variable, 0 = never- and past-smokers and 1 = current-smokers), pack-years of smoking (continuous variable), and a SNP-by-smoking interaction product term. Two of the 19 studies (FHS and TwinsUK) had much relatedness among participants, and we took appropriate account of relatedness in the association testing (Table S12). Four regression models with interaction terms for ever-smoking or pack-years were specified in relation to standardized residuals for FEV1/FVC or FEV1. As it has long been advised in studying interactions, the regression models were designed to fully saturate the main smoking effect on pulmonary function, so that the interaction terms do not capture residual main effects [77]. In each of the 19 studies, the genome-wide analyses were implemented with robust variance estimation using the software packages indicated in Table S12. Our analyses were aimed at finding novel loci associated with pulmonary function when considering an interaction with cigarette smoking, so we chose to implement JMA of SNP main and interactive SNP-by-smoking effects (two d. f. test of the null hypothesis βSNP = 0 and βINT = 0) [15]. Manning et al. previously compared the joint methods, such as JMA, with other methods that incorporate gene-environment interaction (such as screening by main effects [78] or conducting a 1 d. f. meta-analysis of the interaction product term), and they found that the joint methods offer optimal statistical power over a range of scenarios for SNP main and interactive effects [15], [33]. Therefore, our analyses centered on the JMA method, which simultaneously estimates regression coefficients for the SNP and SNP-by-smoking interaction terms, while accounting for their covariance, to generate a joint test of significance [15]. It also accounts for the unequal variances from studies of different sample sizes. Secondarily, we implemented meta-analyses of just the β coefficient from the interaction term for comparison with the JMA results. Of note, the two-step gene-environment interaction study designs by Murcray et al. [79], [80] and Gauderman et al. [81] are applicable to case-control or case-parent trio studies, respectively, and were thus not considered for our population-based studies of continuous traits. The JMA was conducted with fixed effects on approximately 2. 5 million SNPs using METAL software (version 2010-02-08) [82] and patch source code provided by Manning et al. [82]. Genomic control correction was applied by computing λgc as the ratio of the observed and expected (2 d. f.) median chi-square statistics and dividing the observed chi-square statistics by λgc. SNPs having PJMA<5×10−8 (the standard Bonferroni-adjusted P value) were considered statistically significant [83]. Further correction for the four different (albeit related) JMA models yielded a conservative PJMA threshold of 1. 25×10−8. In addition to reporting the PJMA for the most significant SNP from each novel locus, we used the β and standard error (SE) estimates from the JMA results to calculate the P values corresponding to the SNP main association (PSNP) and the SNP-by-ever-smoking interaction (PINT) [15]. Gene annotation was performed using the gene prediction tracks “UCSC Genes” and “RefSeq Genes” in the UCSC browser (http: //genome. ucsc. edu). The “sno/miRNA” track from the USCS browser was used to search for any microRNA within 100 kb upstream or downstream of each SNP, and the “TFBS Conserved” track was used to search for conserved transcription factor binding sites (TFBSs) at or near the most significant SNPs. The SNAP program [84] was used to infer LD patterns, based on the HapMap phase II CEU population. We used separate types of expression analyses to confirm the biologic plausibility of our findings. First, we carried out mRNA expression profiling to show whether or not the implicated genes are expressed in human tissues relevant to pulmonary function. The mRNA expression profiles of implicated genes were determined using reverse transcription polymerase chain reaction (RT-PCR). RNA was sourced from lung (Ambion/ABI), human bronchial epithelial cells (Clonetics) [85], and peripheral blood mononuclear cells (3H Biomedica). RNA from human airway smooth muscle cells, cultured as previously described from tissue obtained at thoracotomy [86], was extracted using a commercially available kit (Qiagen). Ethical approval for the use of primary cells was obtained from the local ethics committees. cDNA was generated using 1 µg of RNA template using random hexamers and a SuperScript kit (Invitrogen) as directed by the manufacturer. PCR assays were designed to cross intron-exon boundaries, where possible and where splice variation was known, in order to detect all variants. The GAPDH gene was used as a positive control for the cDNA quality, and water was used as a negative control. Primer sequences for the genes of interest are given in Table S14. All PCR were done using Platinum Taq High Fidelity (Invitrogen) with 100 ng of cDNA template in a 25 µL reaction. Cycling conditions were as follows: 94°C for 2 minutes, 35 cycles of 94°C for 45 seconds, 55°C for 30 seconds, and 68°C for 90 seconds. Following PCR, gel bands were directly sequenced to confirm the presence of the gene' s transcript. Second, we used another publically available data repository to investigate whether any of the implicated genes showed evidence for differential expression depending on smoking history. The gene expression profiles of human airway epithelium from healthy smokers (N = 10) and nonsmokers (N = 12) were obtained from the Gene Expression Omnibus site (http: //www. ncbi. nlm. nih. gov/geo/) [27], [28], based on robust multichip average processing of probe intensities from Affymetrix HG-U133 Plus 2. 0 microarrays (GEO dataset number GSE4498) [29]. Mean expression levels of genes around our genome-wide significant findings from the JMA were compared between smokers versus nonsmokers. The P value for the difference in means between smokers and nonsmokers was calculated using the nonparametric Mann-Whitney test. Third, our genome-wide significant SNPs from novel loci were searched against an expression quantitative trait loci (eQTL) data repository based on lymphoblastoid cell lines [32], to investigate whether any of the implicated SNP variants might influence the expression of the nearby genes. P<5×10−8 was used to designate statistically significant eQTL associations.
Measures of pulmonary function provide important clinical tools for evaluating lung disease and its progression. Genome-wide association studies have identified numerous genetic risk factors for pulmonary function but have not considered interaction with cigarette smoking, which has consistently been shown to adversely impact pulmonary function. In over 50,000 study participants of European descent, we applied a recently developed joint meta-analysis method to simultaneously test associations of gene and gene-by-smoking interactions in relation to two major clinical measures of pulmonary function. Using this joint method to incorporate genetic main effects plus gene-by-smoking interaction, we identified three novel gene regions not previously related to pulmonary function: (1) DNER, (2) HLA-DQB1 and HLA-DQA2, and (3) KCNJ2 and SOX9. Expression analyses in human lung tissue from ours or prior studies indicate that these regions contain genes that are plausibly involved in pulmonary function. This work highlights the utility of employing novel methods for incorporating environmental interaction in genome-wide association studies to identify novel genetic regions.
genome-wide association studies
medicine
public health and epidemiology
genome scans
pulmonology
smoking related disorders
genome analysis tools
genetic epidemiology
epidemiology
respiratory medicine
biology
public health
environmental health
genetic association studies
genetics
genomics
genetics of disease
genetics and genomics
human genetics
Genome-Wide Joint Meta-Analysis of SNP and SNP-by-Smoking Interaction Identifies Novel Loci for Pulmonary Function